Although several FDA-approved drugs are available to counteract the later effects of hematopoietic acute radiation syndrome (H-ARS), no FDA-approved medical countermeasures have been approved to ...

a novel potential treatment for hematopoietic complications of the acute radiation syndrome (H-ARS) following exposure to nuclear radiation, in response to heightened global tensions and ...

Application error: a client-side exception has occurred (see the browser console for more information).

Pluri (PLUR) announced that it is assessing its readiness to initiate mass production of PLX-R18, a novel potential treatment for hematopoietic complications of the acute radiation syndrome, H-ARS, ...